Novel treatment for high-risk primary prostatic extra-gastrointestinal stromal tumor: a case report and review of the literature

Li Lu,Dejuan Wang,Zhongyang Wang,Hu Qu,Bo Ma,Bing Yao,Wenwen Zhong,Lei Ye,Donglin Ren,Jianguang Qiu

DOI: https://doi.org/10.3877/cma.j.issn.1674-3253.2019.05.015

2019-01-01

Abstract:Objective To discuss the clinical characteristics and treatment for a rare case of the high-risk primary prostatic extra-gastrointestinal stromal tumor (PEGIST). Methods The hospital registry of patient and the related literature analyzed retrospectively and reviewed. Results A 65 years old male patients with the complaint of intermittent hematuria for three months and admitted in our institute. MRI showed that a giant solid pelvic mass (115 mm×105 mm×85 mm) with unknown origin, transrectal biopsy was performed, and pathological results were spinal cell tumor with the suspect from prostate or rectal mesentery. A laparotomy was prescribed, with the radical prostatocystotomy, standard pelvic lymph node resection, Bricker ileal conduit diversion, Postoperative pathological results were high-risk primary PEGIST according to the aggressive behavior of gastrointestinal stromal tumor workshop. Immunohistochemistry results showed that [(CD117(+); Dog1(+); CD34(+); PSA(+); AR(+); P504s(+); Ki-67(2%) ]. Whole-exome sequencing (WES) results identified it harbored with the significant clinical Kit defect (Exon 11 p.Q556-V560del) and the therapeutic candidate of Imatinib mesylate for adjuvant therapy. No signs of recurrence and drug-related complications occurred after 18 months follow-up. Conclusions Primary prostatic EGIST need to be differentiated from other benign and malignant prostatic diseases, and WES identified the underlying genetic defect in rare cases referred for evaluation of a possible genetic condition and decision of drug candidate. Key words: Primary; Prostate; Extra-gastrointestinal stromal tumor; Whole-exome sequencing; Precision medicine